8K33
SOD1 and Nanobody1 complex
8K33 の概要
| エントリーDOI | 10.2210/pdb8k33/pdb |
| 分子名称 | Superoxide dismutase [Cu-Zn], NB1, ZINC ION, ... (4 entities in total) |
| 機能のキーワード | antibody complex, oxidoreductase/immune system, oxidoreductase-immune system complex |
| 由来する生物種 | Homo sapiens (human) 詳細 |
| タンパク質・核酸の鎖数 | 24 |
| 化学式量合計 | 341459.22 |
| 構造登録者 | |
| 主引用文献 | Cheng, S.,Zhong, C.,Zhu, H.,Mu, K.,Jiang, H.,Zhong, P.,Ma, Z.,Liu, X.,Wang, Z.,Liu, R.,Ding, Y. Structural mechanisms and insights on multiple nanobodies binding diverse SOD1 epitopes. Commun Biol, 9:30-30, 2025 Cited by PubMed Abstract: Copper/zinc superoxide dismutase (SOD1) is a crucial metalloenzyme that mitigates oxidative stress by scavenging superoxide anion radicals. Mutations and aggregation of SOD1 are closely linked to the pathogenesis of amyotrophic lateral sclerosis (ALS). Targeting pathogenic SOD1 with nanobodies presents a promising therapeutic approach. We report the first high-resolution crystal structures of SOD1 in complex with three distinct nanobodies (Nb1, Nb2, and Nb3) and their multimeric assemblies (1:2 and 1:3 stoichiometries), revealing distinct binding epitopes primarily mediated by their complementarity determining regions (CDRs) through hydrogen bonds, salt bridges, and hydrophobic interactions. Structural and biophysical analyses using isothermal titration calorimetry (ITC) and fluorescence-detection size-exclusion chromatography (FSEC) demonstrated that all three nanobodies bind SOD1 simultaneously with nanomolar affinities (K values ranging from 23.2 nM to 529 nM). Notably, engineered multimeric tandem nanobodies (Nb1-Nb2-Nb3) achieved higher affinity (K = 4.39 nM) compared to single nanobodies, as validated by ITC. Characterization via dynamic light scattering (DLS) further revealed colloidal stability of SOD1-nanobody complexes. These results provide the first atomic-resolution insights into multi-nanobody targeting of SOD1 without steric interference, establishing a foundation for developing high-affinity tools to detect and manipulate SOD1 in ALS and related neurodegenerative diseases. PubMed: 41350409DOI: 10.1038/s42003-025-09293-0 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.13 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






